A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

NCT01672450 | Completed Phase 1 DMC

• 1 other identifier: HCI56809
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single center, open phase I dose escalation study. This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV melanoma with accessible cutaneous, subcutaneous, and/or nodal lesions. The objective is to primarily assess the safety of the drug combination, and to secondarily obtain preliminary data on the clinical efficacy of the combination.

Conditions

Melanoma

Keywords

Histologically or cytologically proven melanoma; Stages III-IV; accessible cutaneous, subcutaneous, and/or nodal lesions; ECOG performance status 0 to 2

Outcome Measures

Primary Outcomes (1)

• Number of Adverse Events per patient

  To assess safety of interleukin-2 and Ipilimumab combination and to select the recommended dose regimen for future phase II studies

  24 months

Secondary Outcomes (2)

• Starting and Ending measurements of treated lesions

  24 months

• Starting and ending measurement of untreated lesions

  24 months

Study Arms (1)

All patients

EXPERIMENTAL

All participants in this study will receive the same treatment.

Drug: Intratumoral Ipilimumab and Interleukin-2

Interventions

Intratumoral Ipilimumab and Interleukin-2 DRUG

Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks

All patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- Histological diagnosis of melanoma, unresectable stages III-IV with accessible cutaneous, subcutaneous, and/or nodal lesions , according to the AJCC Staging Manual, 7th Edition, 2011.
• Note: Patients who are considered to have resectable disease but decline resection are eligible.
• At least one lesion \> 0.5 cm and \< 2 cm
• ECOG performance status 0, 1 or 2
• Negative pregnancy test for women of childbearing potential within 7 days of enrollment on study.
• WBC \> 2,000/mm3; ANC \> 1,000/mm3; platelet \> 100,000/mm3;hemoglobin \> 9 gm/dL (may be transfused)
• Serum bilirubin levels \<1.5 mg/dL except for patients with Gilbert's syndrome.
• Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) \< 2.5 X upper limit of normal, alkaline phosphatase \< 2.5 X upper limit of normal.
• Serum creatinine levels \<1.5 mg/dL
• Women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father a child while receiving treatment with ipilimumab or interleukin-2. Patients should agree to use an appropriate method of birth control while on study. Examples of adequate forms of birth control for women include oral or implanted contraceptives, intrauterine device (IUD), diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner and also based on the judgment of the investigator.
• Age \> 18 years and of any gender or race.
• Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.

You may not qualify if:

• Concurrent therapy with any other non-protocol anti-cancer therapy
• Prior local therapy within 2 weeks or prior systemic therapy within 4 weeks of starting protocol treatment
• History of any other malignancy requiring active treatment
• Pre-existing autoimmunity: History of inflammatory bowel disease; history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo is allowed.
• Chronic use immunosuppressants or systemic corticosteroids. Note: Chronic use is defined as requiring corticosteroids for greater than one month prior to enrollment on study. Corticosteroid use for less than 1 month prior to enrollment is allowed, but use must stop prior to starting study treatment.
• Clinically significant cardiovascular disease (e.g., uncontrolled hypertension \[BP \>150/100\], myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
• Currently active systemic infection
• Known history of HIV infection or chronic hepatitis B or C.
• The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
• Pregnancy or breast feeding
• A history of a severe hypersensitivity reaction to ipilimumab or interleukin-2
• Any reason why, in the opinion of the investigator, the patient should not participate

Sponsors & Collaborators

• University of Utah: lead

Study Sites (1)

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

Location

MeSH Terms

Conditions

Melanoma

Interventions

Interleukin-2

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Interleukins; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Lymphokines; Proteins; Biological Factors

Study Officials

• Hung Khong, MD

  Huntsman Cancer Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 21, 2012
• First Posted: August 24, 2012
• Study Start: September 1, 2012
• Primary Completion: August 1, 2014
• Study Completion: August 1, 2014
• Last Updated: July 8, 2015

Record last verified: 2015-07

Locations

US (1)